Top 3 Health Care Stocks That May Collapse This Quarter
Top 3 Health Care Stocks That May Collapse This Quarter
As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年12月11日，醫療保健板塊的三隻股票可能向重視交易決策中動量作爲關鍵標準的投資者發出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
相對強弱指數（RSI）是一種動量指標，它比較股票在價格上漲時的強度與在價格下跌時的強度。與股票的價格動態相比，它可以讓交易者更好地了解股票在短期內的表現。根據Benzinga Pro的說法，當RSI超過70時，資產通常被視爲超買。
Here's the latest list of major overbought players in this sector.
以下是該板塊最新的主要超買股票名單。
Adaptive Biotechnologies Corp (NASDAQ:ADPT)
Adaptive Biotechnologies Corp (納斯達克:ADPT)
- On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in guiding blood cancer treatment decisions. The company's shares gained around 6% over the past month and has a 52-week high of $7.07.
- RSI Value: 75.83
- ADPT Price Action: Shares of Adaptive Biotechnologies gained 4.2% to close at $6.71 on Tuesday.
- 在2024年ASH大會上，Adaptive Biotechnologies於12月7日展示了新數據，展示了clonoSEQ MRD測試的進展及其在指導血癌治療決策中的作用。該公司的股票在過去一個月上漲了大約6%，並且在過去52周內的最高價爲$7.07。
- RSI值：75.83
- ADPT價格走勢：Adaptive Biotechnologies的股票在週二上漲了4.2%，收於$6.71。
NewAmsterdam Pharma Company NV (NASDAQ:NAMS)
NewAmsterdam Pharma Company NV (納斯達克:NAMS)
- On Dec. 10, NewAmsterdam Pharma revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The company's stock gained around 30% over the past five days and has a 52-week high of $26.36.
- RSI Value: 81.17
- NAMS Price Action: Shares of NewAmsterdam Pharma jumped 41.4% to close at $26.19 on Tuesday.
- 12月10日，NewAmsterdam Pharma公佈了其第3期BROADWAY臨床試驗的頂線數據，該試驗評估了在動脈粥樣硬化性心血管疾病（ASCVD）和/或雜合子家族性高膽固醇血癥（HeFH）成年患者中使用obicetrapib，儘管接受了最大耐受劑量的降脂治療，但其LDL-C未得到充分控制。公司的股票在過去五天內上漲了約30%，其52周高點爲26.36美元。
- RSI值：81.17
- NAMS價格動態：NewAmsterdam Pharma的股票在週二上漲了41.4%，收於26.19美元。
Paragon 28 Inc (NYSE:FNA)
Paragon 28 Inc (紐交所:FNA)
- On Nov. 12, Paragon 28 reported quarterly losses of 15 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $62.30 million which beat the analyst consensus estimate of $60.58 million. The company's stock gained around 38% over the past month and has a 52-week high of $14.79.
- RSI Value: 77.07
- FNA Price Action: Shares of Paragon 28 gained 5% to close at $10.50 on Tuesday.
- 11月12日，Paragon 28報告每股損失15美分，符合分析師共識預期。該公司報告季度銷售額爲6230萬美元，高於分析師共識預期的6058萬美元。公司的股票在過去一個月內上漲了約38%，其52周高點爲14.79美元。
- RSI值：77.07
- FNA價格動態：Paragon 28的股票在週二上漲了5%，收於10.50美元。
Read This Next:
接下來請閱讀：
- Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear & Greed Index Remains In 'Neutral' Zone
- 道瓊斯連續第四個交易日下跌，Alphabet因谷歌量子芯片公告而飆升：恐懼與貪婪指數仍處於『中立』區域